Last reviewed · How we verify

NCT06791473

AI-Driven Cancer Diagnosis and Prediction With EHR

Recruiting now Last updated 30 July 2025
What this trial tests

trial testing AI-Based Diagnostic and Prognostic Model in Tumor in 1,000,000 participants. Currently enrolling.

Timeline
19 January 2025
Primary endpoint
1 October 2025
1 October 2025

Quick facts

Lead sponsorThe Eye Hospital of Wenzhou Medical University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000,000
Start date19 January 2025
Primary completion1 October 2025
Estimated completion1 October 2025
Sites7 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

The Eye Hospital of Wenzhou Medical University

Who can join

Adults 0 to 90, any sex, with Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for identifying and diagnosing cancer, leveraging multimodal health data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tumor

Currently open trials in the same condition.

Other The Eye Hospital of Wenzhou Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06791473.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing